Leland Health review

Leland’s August 18, 2026 legal page identifies Inverse Collective LLC, doing business as Leland Health, as the technology and administrative-services company. It names OpenLoop Healthcare Partners, PC and affiliated professional entities as medical groups, with independent pharmacies dispensing prescriptions.

The site has treatment menus, prices and patient-platform links. However, its FAQ says treatment availability has not been published for a future patient journey and that confirmed states will accompany enrollment details. Those conflicting signals do not establish that a reader can currently obtain care. This profile is a review of the public offer, not a recommendation to enroll.

Leland advertises semaglutide injections from $129 per four weeks, tirzepatide injections from $219 and semaglutide tablets from $179. The pricing page expressly labels these as starting prices, so they should not be treated as every-dose quotes. Four-week billing renews sooner than billing once per calendar month.

The price FAQ includes the medical evaluation and compounded medication. The same page tells readers to check whether shipping, supplies, labs and follow-ups add charges. Those items are not established as universally included by the public price list. Obtain a complete written quote if the provider confirms that the service is available.

The pricing page says refund terms are being finalized and directs questions to support. The legal page already publishes a refund policy: a declined treatment order is refundable, potentially less a completed consultation fee where permitted, and medication becomes nonrefundable once compounding begins or the order ships.

The legal page also describes replacements for damaged, lost or incorrect shipments reported within fourteen days of delivery and a five-to-ten-business-day processing window for issued refunds. Because the pricing page does not agree that these terms are final, request the applicable version before paying. A generic full-refund assumption would overlook the consultation-fee exception.

The price page says plans automatically renew every four weeks and cancellation should be requested at least 72 hours before the next billing date. The legal terms permit cancellation through the account or support email, effective at the end of the current period.

The terms also allow price changes with at least thirty days’ notice before renewal. If a plan becomes available, keep the exact charge date, cancellation confirmation and applicable price notice together. Canceling future renewals does not necessarily recover money for an order already being prepared.

The FAQ says a clinician reviews the intake and may require a phone or video visit. It does not publish confirmed state availability, and it directs readers not to send medical information through the marketing website. The presence of an intake link alone does not resolve those limits.

Leland identifies its medications as compounded. Its oral semaglutide tablets should not be assumed to have the same absorption, dose or evidence as an FDA-approved oral product, and its compounded injections are not approved generic substitutes. A prescriber would need to explain the particular preparation and why it fits the patient’s needs.

Leland supplies more public information about prices and legal responsibilities than a simple coming-soon page. The unresolved issue is whether the current enrollment path, available states and final billing policies actually match those descriptions.

We would want a confirmed treatment-specific state list, the applicable clinical group and pharmacy, a full dose-specific price, and reconciled refund terms before treating Leland as an established current option. Those inconsistencies make it difficult to recommend starting treatment through the site today.